TrialClinical lung cancer2022

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.

Steven E Schild et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.